Chronic moderate hyperglycaemia does not affect early infarct size or mortality after myocardial infarction in mice: Preliminary results

Diabetologia Doswiadczalna i Kliniczna

Volumn 6, Issue 6, 2006, Pages 309-313

  Kamiński, Karol ^a   Szepietowska, Barbara ^b,e   Szelachowska, Małgorzata ^b   Karwowski, Wojciech ^c   Kozuch, Marcin ^a   Leszczyńska, Agnieszka ^c   Usowicz Szaryńska, Monika ^a   Sawicki, Bogusław ^d   Musiał, Włodzimierz ^a   Górska, Maria ^b   Winnicka, Maria ^c  

^a Klinika Kardiologii Akademii Medycznej W Bia ymstoku

^b Klinika Endokrynologii   (Poland)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d Zaklad Histologii I Embriologii Akademii Medycznej W Bia ymstoku

^e Klinika Endokrynologii   (Poland)

Author keywords

Diabetes; MLD STZ; Mouse; Myocardial infarction

Indexed keywords

GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HISTOPATHOLOGY; HYPERGLYCEMIA; MALE; MORTALITY; MOUSE; NONHUMAN;

EID: 33947251705     PISSN: 16433165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. World Health Organization Diabetes Mellitus: Report of a WHO Study Group. Geneva. World Health Org; 1985: Report No.: Tech. Rep. Ser., no. 727.
2. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? Journal of Internal Medicine 2000; 247: 301-310.
3. Reisin E, Alpert MA. Definition of the metabolic syndrome: current proposals and controversies. Am J Med Sci 2005; 330: 269-272.
4. Dhalla N, Liu X, Panagia V, Takeda N. Subcellular remodelling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998; 40: 239-247.
5. Szelachowska M. Kardiomiopatia cukrzycowa. In: Kinalska I. ed. Problemy kardiologiczne cukrzycy. Medical Press, Gdańsk 2001: 122-124.
6. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
7. Kowalska I, Prokop J, Bachórzewska-Gajewska H et al. Disturbances of glucose metabolism in men referred for coronary arteriography. Postload glycemia as predictor for coronary atherosclerosis. Diabetes Care 2001; 24: 897-901.
8. Meier JJ, Deifuss S, Klamann A et al. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care 2005; 28: 2551-2553.
9. Scott DS, Sutton MJ, Lamas GA et al. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 2002; 106: 1251-1255.
10. Mozaffari MS, Schaffer SW. Effect of hypertension and hypertension-glucose intolerance on myocardial ischemic injury. Hypertension 2003; 42: 1042-1049.
11. Ravingerova T, Neckar J, Kolar F. Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetes. Mol Cell Biochem 2003; 249: 167-174.
12. Marfella R, D'Amico M, Di Filippo C et al. Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia 2002; 45: 1172-1181.
13. Jones SP, Trocha SD, Lefer DJ. Cardioprotective actions of endogenous IL-10 are independent of iNOS. Am J Physiol Heart Circ Physiol 2001; 281: H48-H52.
14. Shiomi T, Tsutsui H, Ikeuchi M et al. Streptozotocin-induced hyperglycemia exacerbates left ventricular remodeling and failure after experimental myocardial infarction. J Am Coll Cardiol 2003; 42: 165-172.
15. Like AA, Rossini AA. Streptozocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976; 193: 415-417.
16. Fuchs M, Hilfiker A, Kaminski K et al. Role of interleukin-6 for left ventricular remodeling and survival after experimental myocardial infarction. FASEB J 2003; 17: 2118-2120.
17. Wang Z, Gleichmann H. GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes 1998; 47: 50-56.
18. Toye AA, Lippiat JD, Proks P et al. A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. Diabetologia 2005; 48: 675-686.
19. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002; 136: 54-71.
20. Capes S, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview (Review). Lancet 2000; 355: 773-778.
21. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality on conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-2632.
22. Malmberg K, Ryden L, Wedel H et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-661.